Tissue engineering

Kirigami hydrogels rise from cellulose film

Retrieved on: 
금요일, 4월 12, 2024
Science, Nanofiber, Gel, University of Tokyo, Swelling, Administration, Hydrogel, Research, Kirigami, Water, The Journal, Cellulose, Tissue engineering, Movement, Growth, Advanced Materials

Their work extends the emerging field of 'kirigami hydrogels', in which patterns are cut into a thin film allowing it to later swell into complex hydrogel structures.

Key Points: 
  • Their work extends the emerging field of 'kirigami hydrogels', in which patterns are cut into a thin film allowing it to later swell into complex hydrogel structures.
  • Researchers Daisuke Nakagawa and Itsuo Hanasaki worked with an initially dry film composed of nanofibers of cellulose, the natural material that forms much of the structure of plant cell walls.
  • They used laser processing to cut structures into the film before water was added allowing the film to swell.
  • The advance in kirigami hydrogels achieved by the TUAT team significantly extends the options for future hydrogel applications.

Induced Pluripotent Stem Cell (iPSC) Industry Market Size, Trends, and Forecast Report - ResearchAndMarkets.com

Retrieved on: 
화요일, 5월 7, 2024
Health, Stem Cells, OA, Cellular Dynamics International, University, Microsoft Exchange Server, Cell, CRISPR, Safety, Drug development, Osteoarthritis, World Games, MSC, Partnership, Research, CLI, B cell, Application, Disease, Human, Therapy, Patient, COVID-19, Tissue engineering, Graft-versus-host disease, IPSC, Medicine, Kyoto University, 3D bioprinting, Macular degeneration, Regenerative medicine, CDI, Clinical trial, Toxicology, Drug discovery, Personalized medicine, Merck, Thermo Fisher Scientific, Pharmaceutical industry

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
    Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development.

CytoHub Bolsters Team with Top Industry Experts to Enhance Leadership in Cell Therapy and Regenerative Medicine Innovation

Retrieved on: 
월요일, 5월 6, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Cloud, Cell, Biomedical engineering, MSU, Artificial intelligence, Biomedicine, Machine learning, Tissue engineering, IPSC, Lead, Regenerative medicine, Biology, GMP, Associate, Technical, Medical device

CytoHub, Inc. , a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, today announced the strategic addition of three top industry experts to its team.

Key Points: 
  • CytoHub, Inc. , a pioneering developer of intelligent technologies for cell therapy and regenerative medicine, today announced the strategic addition of three top industry experts to its team.
  • These appointments mark a significant enhancement of CytoHub’s leadership, aligning with the company’s commitment to advancing biomanufacturing innovations in cell therapy and regenerative medicine.
  • David DiGiusto, Ph.D., brings over three decades of experience in translational medicine and GMP compliant iPSC derived cells as therapeutics agents and biologics manufacturing.
  • CytoHub is at the forefront of this industrialized biology, driving cell therapy and regenerative medicine innovations.

Nanofibers Industry Poised for Exponential Growth: 26% CAGR Anticipated from 2023 to 2028

Retrieved on: 
목요일, 5월 2, 2024
Ceramic, Nanofiber, Filtration, Investment, Glass, Key market, Metal, International finance, Transport, Semiconductor, Carbon, Food industry, Polymer, Tissue engineering, Electronics, Regenerative medicine, Alloy, Growth, Row

BOSTON, May 2, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Global Markets and Technologies for Nanofibers is growing from $2.9 billion in 2023 to $9.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.0% from 2023 through 2028."

Key Points: 
  • Applications: Nanofibers find diverse uses across industries, from life sciences to transportation, contributing to advancements in tissue engineering, filtration, energy storage, electronics, and sensing technologies.
  • Regions: The global nanofiber market sees significant activity in North America, Europe, Asia-Pacific, and emerging markets worldwide, driving innovation and adoption.
  • The global market for nanofibers is projected to grow from $2.4 billion in 2022 to $9.4 billion in 2028 at a compound annual growth rate (CAGR) of 26.0% during the forecast period.
  • The key factors driving the growth of the nanofibers market include:
    Advances in the life science sector.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
수요일, 5월 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Global Functional Dyspepsia Drug Market to reach a valuation of US$ 16.4 billion by 2034, Future Market Insights, Inc. Projection

Retrieved on: 
수요일, 5월 1, 2024
Gastroenterology, Transplant, Acupuncture, Indigestion, Research, Laboratory, Probiotic, Abbott Laboratories, Herbal, Therapy, Patient, Tissue engineering, Enzyme inhibitor, Regenerative medicine, Collaboration, Market, Diagnosis, Antacid, Drug development, Regeneration, Ageing, Investment, Nutritional science, Pharmaceutical industry

NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population. The trend is set to create new opportunities for the market, leading to a projected CAGR of 4.8% between 2024 and 2034, and reaching a total valuation of approximately US$ 16.4 billion by 2034.

Key Points: 
  • NEWARK, Del., May 1, 2024 /PRNewswire/ -- The global functional dyspepsia drug market will reach a valuation of US$ 10.3 billion in 2024, attributed to factors such as increasing geriatric population.
  • Collaboration between pharmaceutical companies, academic institutions, and research organizations fosters innovation in functional dyspepsia drug development.
  • Key Takeaways from the Market Study:
    Global functional dyspepsia drug market was valued at US$ 9.7 billion in 2023.
  • The functional dyspepsia drug market is characterized by a diverse array of pharmaceutical companies, research institutions, and healthcare organizations striving to develop and commercialize innovative treatments for functional dyspepsia.

Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)

Retrieved on: 
목요일, 4월 18, 2024
Health, Hospitals, Other Health, Other Science, General Health, Research, Science, Education, FDA, Rheumatology, EVS, Microsoft Exchange Server, Intervertebral disc, Regenerative medicine, Seminal vesicles, Cartilage, Doctor of Philosophy, B cell, Meniscus, ICRS, Patient, Tissue engineering, Molecular medicine, 3D bioprinting, Medical research, Microsoft Access, Multimedia, Regeneration, Stem cell, Credit, Journal, Medical device

The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.

Key Points: 
  • The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.
  • View the full release here: https://www.businesswire.com/news/home/20240418363701/en/
    Feinstein Institutes’ Dr. Daniel A. Grande has been named the new president-elect of International Cartilage Repair Society.
  • (Credit: Feinstein Institutes)
    Dr. Grande, renowned for his significant contributions to cartilage repair and regeneration, will lead the ICRS in its mission to advance science and education in preventing and treating cartilage injuries.
  • "I am honored and excited to serve as the President-Elect of the International Cartilage Regeneration & Joint Preservation Society.

MUSCLE CULTIVATION STARTUP PROFUSE-TECHNOLOGY WELCOMES RENOWNED TECHNION PROFESSOR TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
월요일, 4월 22, 2024
Diabetes, Biomedical engineering, Weight loss, Research, Duchenne, Weizmann Institute of Science, Obesity, Biomedicine, Therapy, Cachexia, Patient, Tissue engineering, Regenerative medicine, Sarcopenia, Duchenne muscular dystrophy, Faculty, Ageing, Biotechnology, Pharmaceutical industry

YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration. The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.

Key Points: 
  • YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration.
  • The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.
  • She has joined ProFuse Technology's Scientific Advisory Board to bolster the company's effort to develop materials and methodologies for muscle regeneration and maintenance.
  • We are thrilled to welcome Professor Levenberg's to our Scientific Advisory Board, in order to bolster our pioneering innovative approaches towards muscle regeneration and maintenance."

X-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)

Retrieved on: 
수요일, 4월 17, 2024
FDA, Drug discovery, Cell, Risk, Food, Therma, Commercialization, CDER, Vaccine, IND, A-DNA, Drug Master File, SVP, Cryopreservation, Chemistry, CMC, Tissue engineering, Regenerative medicine, BLA, Peptoid, MBA, GMP, DMF, SAN, Biotechnology, Investigational New Drug, Pharmaceutical industry

SAN FRANCISCO, April 17, 2024 /PRNewswire/ -- X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive®.

Key Points: 
  • SAN FRANCISCO, April 17, 2024 /PRNewswire/ -- X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive®.
  • This DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines.
  • X-Therma submitted the DMF to the FDA in January 2024, and the FDA accepted it on January 31, 2024.
  • "It is the plug-and-play solution for cell and tissue manufacturing processes to enable greater bioproduction scale-up, reliability, and consistency."

Vesigen to Present at the 2024 Cell and Gene Meeting on the Med

Retrieved on: 
수요일, 4월 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, MED, Tissue engineering, Cell, Regenerative medicine, RNA, Gene editing, Therapy

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2024 Cell and Gene Meeting on the Med on April 10th at 10:45 AM CET in Rome, Italy.
  • Virtual attendance is available which includes a livestream of Vesigen’s presentation and the ability to view all conference sessions on-demand.
  • Visit https://meetingonthemed.com/ for full information including registration.
  • Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Med is a three-day conference featuring more than 60 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as over 100 panelists and featured speakers.